Sarcoma immunotherapy: Past approaches and future directions

Sarcoma

Volumn 2014, Issue , 2014, Pages

  D'Angelo, S P ^a,b   Tap, W D ^a,b   Schwartz, G K ^a,b   Carvajal, R D ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DASATINIB; GANGLIOSIDE; INTERLEUKIN 2; IPILIMUMAB; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE ANTIGEN; NIVOLUMAB; RECOMBINANT ALPHA2A INTERFERON;

ADAPTIVE IMMUNITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL TRANSFER; CLINICAL TRIAL; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; SARCOMA;

EID: 84897498395     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2014/391967     Document Type: Review

References (131)

1. Brennan M. F., Antonescu C. R., Maki R. G., Management of Soft Tissue Sarcoma 2012 New York, NY, USA Springer
2. Brennan M. F., Singer S., Maki E., O'Sullivan B., Cancer: Principles and Practice of Oncology 2008 Philadelphia, Pa, USA Lippincott, Williams & Wilkins
3. Lindberg R. D., Martin R. G., Romsdahl M. M., Barkley H. T. Jr., Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer 1981 47 10 2391 2397 2-s2.0-0019445562 (Pubitemid 11127627)
4. Weitz J., Antonescu C. R., Brennan M. F., Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. Journal of Clinical Oncology 2003 21 14 2719 2725 2-s2.0-0043132269 10.1200/JCO.2003.02.026 (Pubitemid 46606317)
5. Billingsley K. G., Burt M. E., Jara E., Ginsberg R. J., Woodruff J. M., Leung D. H. Y., Brennan M. F., Pulmonary metastases from soft tissue sarcoma: analysis of patterns of disease and postmetastasis survival. Annals of Surgery 1999 229 5 602 610 2-s2.0-0033511159 10.1097/00000658-199905000-00002 (Pubitemid 30187567)
6. Van Glabbeke M., Van Oosterom A. T., Oosterhuis J. W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T., Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline- containing first-line regimens-a European organization for research and treatment of cancer soft tissue and bone sarcoma group study. Journal of Clinical Oncology 1999 17 1 150 157 2-s2.0-0032952928 (Pubitemid 29022388)
7. Curiel T. J., Curiel T. J., Historical perspectives and current trends in cancer immunotherapy. Cancer Immunotherapy: Paradigms, Practice and Promise 2012 New York, NY, USA Springer 10.1007/978-1-4614-4732-0-1
8. Coley W. B., II. contribution to the knowledge of sarcoma. Annals of Surgery 1891 14 199 220
9. Wiemann B., Starnes C. O., Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacology and Therapeutics 1994 64 3 529 564 2-s2.0-0028081705 10.1016/0163-7258(94)90023-X (Pubitemid 24381235)
10. American Cancer Society's Guide to Complementary and Alternative Cancer Methods 2000 American Cancer Society
11. Gatti R. A., Good R. A., Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971 28 1 89 98 2-s2.0-0015098830
12. Penn I., Sarcomas in organ allograft recipients. Transplantation 1995 60 12 1485 1491 2-s2.0-0029594585 (Pubitemid 26012684)
13. De Visser K. E., Eichten A., Coussens L. M., Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer 2006 6 1 24 37 2-s2.0-30144443269 10.1038/nrc1782 (Pubitemid 43053650)
14. Mellman I., Coukos G., Dranoff G., Cancer immunotherapy comes of age. Nature 2011 480 7378 480 489 2-s2.0-84255197842 10.1038/nature10673
15. Peggs K. S., Quezada S. A., Korman A. J., Allison J. P., Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Current Opinion in Immunology 2006 18 2 206 213 2-s2.0-33644659256 10.1016/j.coi.2006.01.011 (Pubitemid 43327304)
16. Robert C., Ghiringhelli F., What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 2009 14 8 848 861 2-s2.0-70249083099 10.1634/theoncologist.2009-0028
17. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
18. Kim R., Emi M., Tanabe K., Cancer immunoediting from immune surveillance to immune escape. Immunology 2007 121 1 1 14 2-s2.0-34047220868 10.1111/j.1365-2567.2007.02587.x (Pubitemid 46537674)
19. Teng M. W. L., Swann J. B., Koebel C. M., Schreiber R. D., Smyth M. J., Immune-mediated dormancy: an equilibrium with cancer. Journal of Leukocyte Biology 2008 84 4 988 993 2-s2.0-53549123079 10.1189/jlb.1107774
20. Vajdic C. M., Van Leeuwen M. T., Cancer incidence and risk factors after solid organ transplantation. International Journal of Cancer 2009 125 8 1747 1754 2-s2.0-70349256093 10.1002/ijc.24439
21. Freeman G. J., Long A. J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L. J., Malenkovich N., Okazaki T., Byrne M. C., Horton H. F., Fouser L., Carter L., Ling V., Bowman M. R., Carreno B. M., Collins M., Wood C. R., Honjo T., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. Journal of Experimental Medicine 2000 192 7 1027 1034 2-s2.0-0034596948 10.1084/jem.192.7.1027
22. Nishimura H., Honjo T., PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends in Immunology 2001 22 5 265 268 2-s2.0-0034927194 10.1016/S1471-4906(01)01888-9 (Pubitemid 32667515)
23. + T cells and is overcome by IL-2. European Journal of Immunology 2002 32 3 634 643 (Pubitemid 34257540)
24. Latchman Y., Wood C. R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A. J., Brown J. A., Nunes R., Greenfield E. A., Bourque K., Boussiotis V. A., Carter L. L., Carreno B. M., Malenkovich N., Nishimura H., Okazaki T., Honjo T., Sharpe A. H., Freeman G. J., PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology 2001 2 3 261 268 2-s2.0-5844264920 10.1038/85330 (Pubitemid 33706004)
25. Smyth M. J., Godfrey D. I., Trapani J. A., A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunology 2001 2 4 293 299 2-s2.0-0035320526 10.1038/86297 (Pubitemid 33706339)
26. Swann J. B., Vesely M. D., Silva A., Sharkey J., Akira S., Schreiber R. D., Smyth M. J., Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 2 652 656 2-s2.0-38649087921 10.1073/pnas.0708594105 (Pubitemid 351171763)
27. Burnet M., Cancer, a biological approach. I. The processes of control. British Medical Journal 1957 1 779 786
28. Burnet F. M., The concept of immunological surveillance. Progress in Experimental Tumor Research 1970 13 1 27 2-s2.0-0014887939
29. Burnet M., Immunological factors in the process of carcinogenesis. British Medical Bulletin 1964 20 2 154 158 2-s2.0-0011542558
30. Tsung K., Norton J. A., Lessons from Coley's Toxin. Surgical Oncology 2006 15 1 25 28 2-s2.0-33747873283 10.1016/j.suronc.2006.05.002 (Pubitemid 44293389)
31. Bhardwaj N., Harnessing the immune system to treat cancer. Journal of Clinical Investigation 2007 117 5 1130 1136 2-s2.0-34248192226 10.1172/JCI32136 (Pubitemid 46718397)
32. Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D., Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 2002 3 11 991 998 2-s2.0-0036852241 10.1038/ni1102-991 (Pubitemid 35363648)
33. + T-lymphocyte infiltration and affect tumour progression. Journal of Pathology 2011 223 3 347 357 2-s2.0-78650618910 10.1002/path.2819
34. Brinkrolf P., Landmeier S., Altvater B., Chen C., Pscherer S., Rosemann A., Ranft A., Dirksen U., Juergens H., Rossig C., A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD2 5 hi FoxP3+) in Ewing sarcoma patients is associated with metastatic disease. International Journal of Cancer 2009 125 4 879 886 2-s2.0-67650091383 10.1002/ijc.24461
35. Rusakiewicz S., Semeraro M., Sarabi M., Desbois M., Locher C., Mendez R., Vimond N., Concha A., Garrido F., Isambert N., Chaigneau L., Le Brun-Ly V., Dubreuil P., Cremer I., Caignard A., Poirier-Colame V., Chaba K., Flament C., Halama N., Jäger D., Eggermont A., Bonvalot S., Commo F., Terrier P., Opolon P., Emile J. F., Coindre J. M., Kroemer G., Chaput N., Le Cesne A., Blay J. Y., Zitvogel L., Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Research 2013 73 12 3499 3510 10.1158/0008-5472.CAN-13-0371
36. Jenkins N. H., Freedman L. S., McKibbin B., Spontaneous regression of a desmoid tumour. Journal of Bone and Joint Surgery B 1986 68 5 780 781 2-s2.0-0022976423 (Pubitemid 17177305)
37. Matsuo T., Shimose S., Kubo T., Mikami Y., Arihiro K., Yasunaga Y., Ochi M., Extraskeletal osteosarcoma with partial spontaneous regression. Anticancer Research 2009 29 12 5197 5201 2-s2.0-75149116138
38. Sorbye S. W., Kilvaer T. K., Valkov A., Donnem T., Smeland E., Al-Shibli K., Bremnes R. M., Busund L.-T., Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clinical Pathology 2012 12 article 5 2-s2.0-84857479028 10.1186/1472-6890-12-5
39. Sorbye S. W., Kilvaer T., Valkov A., Donnem T., Smeland E., Al-Shibli K., Bremnes R. M., Busund L.-T., Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 2011 6 1 2-s2.0-79551518508 10.1371/journal.pone.0014611 e14611
40. Crowe N. Y., Smyth M. J., Godfrey D. I., A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. Journal of Experimental Medicine 2002 196 1 119 127 2-s2.0-0036645278 10.1084/jem.20020092 (Pubitemid 34747317)
41. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J., Schreiber R. D., IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 410 6832 1107 1111 2-s2.0-0035953308 10.1038/35074122 (Pubitemid 32391043)
42. Tsukahara T., Kawaguchi S., Torigoe T., Asanuma H., Nakazawa E., Shimozawa K., Nabeta Y., Kimura S., Kaya M., Nagoya S., Wada T., Yamashita T., Sato N., Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Science 2006 97 12 1374 1380 2-s2.0-33750359762 10.1111/j.1349-7006.2006.00317.x (Pubitemid 44614990)
43. Margolin K., Lazarus M., Kaufman H. L., Curiel T. J., Cytokines in the treatment of cancer. Cancer Immunotherapy: Paradigms, Practice and Promise 2012 New York, NY, USA Springer
44. Lippitz B. E., Cytokine patterns in patients with cancer: a systematic review. The Lancet Oncology 2013 14 e218 e228
45. Nelson B. H., IL-2, regulatory T cells, and tolerance. Journal of Immunology 2004 172 7 3983 3988 2-s2.0-1642321982 (Pubitemid 38375208)
46. + T regulatory cells in human neonatal T cell responses to environmental antigens/allergens. Journal of Immunology 2004 173 5 3084 3092 2-s2.0-4344636750 (Pubitemid 39142014)
47. Fagan E. A., Feddleston A. L. W., Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells. Gut 1987 28 2 113 116 2-s2.0-0023137569 (Pubitemid 17027376)
48. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A., Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. Journal of Experimental Medicine 1982 155 6 1823 1841 2-s2.0-0019951384 (Pubitemid 12074218)
49. Yang S. C., Grimm E. A., Parkinson D. R., Carinhas J., Fry Mendiguren-Rodriguez K. D. A., Licciardello J., Owen-Schaub L. B., Hong W. K., Roth J. A., Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor α in patients with advanced non-small cell lung cancer: a phase I trial. Cancer Research 1991 51 14 3669 3676 2-s2.0-0025875880
50. Yang S. C., Owen-Schaub L., Grimm E. A., Roth J. A., Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor- α against primary lung cancer targets. Cancer Immunology Immunotherapy 1989 29 3 193 198 2-s2.0-0024397113 (Pubitemid 19141696)
51. Schwinger W., Klass V., Benesch M., Lackner H., Dornbusch H. J., Sovinz P., Moser A., Schwantzer G., Urban C., Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Annals of Oncology 2005 16 7 1199 1206 2-s2.0-25444441051 10.1093/annonc/mdi226 (Pubitemid 41418325)
52. Atkins M. B., Lotze M. T., Dutcher J. P., Fisher R. I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., Rosenberg S. A., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology 1999 17 7 2105 2116 2-s2.0-0033024863 (Pubitemid 29318842)
53. Atkins M. B., Regan M., McDermott D., Yang J., Bukowski R., Linehan W. M., Lipton A., Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clinical Cancer Research 2004 10 18 6342S 6346S 2-s2.0-4644335916 10.1158/1078-0432.CCR-040029 (Pubitemid 39287489)
54. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E., Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Annals of Surgery 1989 210 4 474 485 2-s2.0-0024426529 (Pubitemid 19242611)
55. Pestka S., The interferons: 50 years after their discovery, there is much more to learn. Journal of Biological Chemistry 2007 282 28 20047 20051 2-s2.0-34547099363 10.1074/jbc.R700004200 (Pubitemid 47099975)
56. Kirkwood J. M., Ibrahim J. G., Sosman J. A., Sondak V. K., Agarwala S. S., Ernstoff M. S., Rao U., High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. Journal of Clinical Oncology 2001 19 9 2370 2380 2-s2.0-0035339880 (Pubitemid 32391207)
57. Kyi C., Postow M. A., Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters 2014 588 368 376 10.1016/j.febslet.2013.10.015
58. Ito H., Murakami K., Yanagawa T., Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma: case reports. Cancer 1980 46 7 1562 1565 2-s2.0-0018972569 (Pubitemid 10003926)
59. Edmonson J. H., Long H. J., Frytak S., Smithson W. A., Itri L. M., Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas. Cancer Treatment Reports 1987 71 7-8 747 748 2-s2.0-0023368740
60. Kager L., Potschger U., Bielack S., Review of mifamurtide in the treatment of patients with osteosarcoma. Therapeutics and Clinical Risk Management 2010 6 279 286
61. Meyers P. A., Schwartz C. L., Krailo M. D., Healey J. H., Bernstein M. L., Betcher D., Ferguson W. S., Gebhardt M. C., Goorin A. M., Harris M., Kleinerman E., Link M. P., Nadel H., Nieder M., Siegal G. P., Weiner M. A., Wells R. J., Womer R. B., Grier H. E., Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the children's oncology group. Journal of Clinical Oncology 2008 26 4 633 638 2-s2.0-39149136228 10.1200/JCO.2008.14.0095 (Pubitemid 351264359)
62. Chou A. J., Kleinerman E. S., Krailo M. D., Chen Z., Betcher D. L., Healey J. H., Conrad E. U. III, Nieder M. L., Weiner M. A., Wells R. J., Womer R. B., Meyers P. A., Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009 115 22 5339 5348 2-s2.0-70449369314 10.1002/cncr.24566
63. Anderson P. M., Meyers P., Kleinerman E., Venkatakrishnan K., Hughes D. P., Herzog C., Huh W., Sutphin R., Vyas Y. M., Shen V., Warwick A., Yeager N., Oliva C., Wang B., Liu Y., Chou A., Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatric Blood & Cancer 2014 61 2 238 244 10.1002/pbc.24686
64. Pollack S. M., Loggers E. T., Rodler E. T., Yee C., Jones R. L., Immune-based therapies for sarcoma. Sarcoma 2011 2011 7 2-s2.0-79953281185 10.1155/2011/438940 438940
65. Müller C. R., Smeland S., Bauer H. C. F., Sæter G., Strander H., Interferon- α as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncologica 2005 44 5 475 480 2-s2.0-23944474283 10.1080/02841860510029978 (Pubitemid 41191780)
66. Strander H., Bauer H. C., Brosjo O., Fernberg J. O., Kreicbergs A., Nilsonne U., Silfversward C., Signomklao T., Soderlund V., Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncologica 1995 34 6 877 880 2-s2.0-0028784363
67. Winkler K., Beron G., Kotz R., Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. Journal of Clinical Oncology 1984 2 6 617 624 2-s2.0-0021612290 (Pubitemid 14025617)
68. Bielack S. S., Whelan J., Marina N., Hook J., Jovic G., Krailo M., Butterfass-Bahloul T., Kühne T., Eriksson M., Teot L., Gelderblom H., Kager L., Sundby Hall K., Gorlick R., Lor Randall R., Hogendoorn P., Calaminus G., Sydes M., Bernstein M., MAP plus maintenance pegylated interferon α -2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 "good response" randomization. Journal of Clinical Oncology 2013 31 supplement, abstract LBA10504
69. Dillman R., Barth N., Selvan S., Beutel L., De Leon C., DePriest C., Peterson C., Nayak S., Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biotherapy and Radiopharmaceuticals 2004 19 5 581 588 2-s2.0-9144252310 10.1089/ 1084978042484812 (Pubitemid 39546297)
70. Geiger J. D., Hutchinson R. J., Hohenkirk L. F., McKenna E. A., Yanik G. A., Levine J. E., Chang A. E., Braun T. M., Mulé J. J., Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Research 2001 61 23 8513 8519 2-s2.0-0035576891 (Pubitemid 33131133)
71. Mackall C. L., Rhee E. H., Read E. J., Khuu H. M., Leitman S. F., Bernstein D., Tesso M., Long L. M., Grindler D., Merino M., Kopp W., Tsokos M., Berzofsky J. A., Helman L. J., A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clinical Cancer Research 2008 14 15 4850 4858 2-s2.0-51049105734 10.1158/1078-0432.CCR-07-4065
72. Pritchard-Jones K., Spendlove I., Wilton C., Whelan J., Weeden S., Lewis I., Hale J., Douglas C., Pagonis C., Campbell B., Alvarez P., Halbert G., Durrant L. G., Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. British Journal of Cancer 2005 92 8 1358 1365 2-s2.0-21044444425 10.1038/sj.bjc.6602500 (Pubitemid 40705000)
73. Suminoe A., Matsuzaki A., Hattori H., Koga Y., Hara T., Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatric Transplantation 2009 13 6 746 753 2-s2.0-68849107068 10.1111/j.1399-3046.2008.01066.x
74. Kawaguchi S., Wada T., Ida K., Sato Y., Nagoya S., Tsukahara T., Kimura S., Sahara H., Ikeda H., Shimozawa K., Asanuma H., Torigoe T., Hiraga H., Ishii T., Tatezaki S.-I., Sato N., Yamashita T., Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. Journal of Translational Medicine 2005 3 article 1 2-s2.0-18044375060 10.1186/1479-5876-3-1 (Pubitemid 40617864)
75. Kawaguchi S., Tsukahara T., Ida K., Kimura S., Murase M., Kano M., Emori M., Nagoya S., Kaya M., Torigoe T., Ueda E., Takahashi A., Ishii T., Tatezaki S., Toguchida J., Tsuchiya H., Osanai T., Sugita T., Sugiura H., Ieguchi M., Ihara K., Hamada K., Kakizaki H., Morii T., Yasuda T., Tanizawa T., Ogose A., Yabe H., Yamashita T., Sato N., Wada T., SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Science 2012 103 9 1625 1630 10.1111/j.1349-7006.2012. 02370.x
76. Wolchok J. D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., Waterfield W., Schadendorf D., Smylie M., Guthrie T. Jr., Grob J.-J., Chesney J., Chin K., Chen K., Hoos A., O'Day S. J., Lebbé C., Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology 2010 11 2 155 164 2-s2.0-75249100054 10.1016/S1470-2045(09)70334-1
77. Maki R. G., Jungbluth A. A., Gnjatic S., Schwartz G. K., D'Adamo D. R., Keohan M. L., Wagner M. J., Scheu K., Chiu R., Ritter E., Kachel J., Lowy I., Old L. J., Ritter G., A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013 2013 8 168145 10.1155/2013/168145
78. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.-F., Testori A., Grob J.-J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H. Jr., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.-T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 2011 364 26 2517 2526 2-s2.0-79959772576 10.1056/NEJMoa1104621
79. Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009 45 2 228 247 2-s2.0-57849117384 10.1016/j.ejca.2008.10.026
80. Wolchok J. D., Hoos A., O'Day S., Weber J. S., Hamid O., Lebbé C., Maio M., Binder M., Bohnsack O., Nichol G., Humphrey R., Hodi F. S., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research 2009 15 23 7412 7420 2-s2.0-73149092567 10.1158/1078-0432.CCR-09-1624
81. Agarwala S. S., Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Research 2010 20 1 1 10 2-s2.0-75749151759 10.1097/CMR.0b013e328333bbc8
82. Maker A. V., Phan G. Q., Attia P., Yang J. C., Sherry R. M., Topalian S. L., Kammula U. S., Royal R. E., Haworth L. R., Levy C., Kleiner D., Mavroukakis S. A., Yellin M., Rosenberg S. A., Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Annals of Surgical Oncology 2005 12 12 1005 1016 2-s2.0-27844458057 10.1245/ASO.2005.03.536 (Pubitemid 41660676)
83. Lee K. C., Ouwehand I., Giannini A. L., Thomas N. S., Dibb N. J., Bijlmakers M. J., Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 2010 24 4 896 900 2-s2.0-77950939774 10.1038/leu.2010.11
84. Ozao-Choy J., Ge M., Kao J., Wang G. X., Meseck M., Sung M., Schwartz M., Divino C. M., Pan P.-Y., Chen S.-H., The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Research 2009 69 6 2514 2522 2-s2.0-65549141834 10.1158/0008-5472.CAN-08-4709
85. Kreutzman A., Juvonen V., Kairisto V., Ekblom M., Stenke L., Seggewiss R., Porkka K., Mustjoki S., Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010 116 5 772 782 2-s2.0-77956280601 10.1182/blood-2009-12- 256800
86. Ray P., Krishnamoorthy N., Oriss T. B., Ray A., Signaling of c-kit in dendritic cells influences adaptive immunity. Annals of the New York Academy of Sciences 2010 1183 104 122 2-s2.0-75749128594 10.1111/j.1749-6632.2009.05122.x
87. Mustjoki S., Ekblom M., Arstila T. P., Dybedal I., Epling-Burnette P. K., Guilhot F., Hjorth-Hansen H., Höglund M., Kovanen P., Laurinolli T., Liesveld J., Paquette R., Pinilla-Ibarz J., Rauhala A., Shah N., Simonsson B., Sinisalo M., Steegmann J. L., Stenke L., Porkka K., Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009 23 8 1398 1405 2-s2.0-68749108104 10.1038/leu.2009.46
88. Balachandran V. P., Cavnar M. J., Zeng S., Bamboat Z. M., Ocuin L. M., Obaid H., Sorenson E. C., Popow R., Ariyan C., Rossi F., Besmer P., Guo T., Antonescu C. R., Taguchi T., Yuan J., Wolchok J. D., Allison J. P., Dematteo R. P., Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine 2011 17 9 1094 1100 2-s2.0-80052493233 10.1038/nm.2438
89. + T cells with IFN- γ -dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. Journal of Immunology 2003 171 11 5931 5939 2-s2.0-0344153890 (Pubitemid 37467211)
90. + helper T cell responses in cancer patients. Blood 2005 106 3 1008 1011 2-s2.0-23044463715 10.1182/blood-2005-02-0607 (Pubitemid 41076447)
91. + regulatory T cells. Journal of Immunology 2005 174 1 90 98 2-s2.0-10844269645 (Pubitemid 40007395)
92. + T-cell-dependent immune defense of B16 melanoma. Cancer Research 2001 61 24 8643 8646 2-s2.0-0035893387 (Pubitemid 34013869)
93. Rabinovich G. A., Gabrilovich D., Sotomayor E. M., Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology 2007 25 267 296 2-s2.0-33947259319 10.1146/annurev.immunol.25.022106.141609 (Pubitemid 46697910)
94. Topalian S. L., Hodi F. S., Brahmer J. R., Gettinger S. N., Smith D. C., McDermott D. F., Powderly J. D., Carvajal R. D., Sosman J. A., Atkins M. B., Leming P. D., Spigel D. R., Antonia S. J., Horn L., Drake C. G., Pardoll D. M., Chen L., Sharfman W. H., Anders R. A., Taube J. M., McMiller T. L., Xu H., Korman A. J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G. D., Gupta A., Wigginton J. M., Sznol M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012 366 26 2443 2454 10.1056/NEJMoa1200690
95. Wolchok J. D., Kluger H., Callahan M. K., Postow M. A., Rizvi N. A., Lesokhin A. M., Segal N. H., Ariyan C. E., Gordon R. A., Reed K., Burke M. M., Caldwell A., Kronenberg S. A., Agunwamba B. U., Zhang X., Lowy I., Inzunza H. D., Feely W., Horak C. E., Hong Q., Korman A. J., Wigginton J. M., Gupta A., Sznol M., Nivolumab plus Ipilimumab in Advanced Melanoma. The New England Journal of Medicine 2013 369 2 122 133 10.1056/NEJMoa1302369
96. Maki R. G., Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Current Opinion in Oncology 2001 13 4 270 274 2-s2.0-0034960246 10.1097/00001622-200107000-00010 (Pubitemid 32578993)
97. Pukel C. S., Lloyd K. O., Travassos L. R., G D3, A prominent ganglioside of human melanoma. Detection and characterization by mouse monoclonal antibody. Journal of Experimental Medicine 1982 155 4 1133 1147 2-s2.0-0020003718 (Pubitemid 12142729)
98. Real F. X., Houghton A. N., Albino A. P., Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Research 1985 45 9 4401 4411 2-s2.0-0022378860 (Pubitemid 16224904)
99. Hamilton W. B., Helling F., Lloyd K. O., Livingston P. O., Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. International Journal of Cancer 1993 53 4 566 573 2-s2.0-0027447521 (Pubitemid 23069265)
100. Zhang S., Cordon-Cardo C., Zhang H. S., Reuter V. E., Adluri S., Hamilton W. B., Lloyd K. O., Livingston P. O., Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. International Journal of Cancer 1997 73 42 49 (Pubitemid 27445989)
101. Cheung N.-K. V., Saarinen U. M., Neely J. E., Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Research 1985 45 6 2642 2649 2-s2.0-0021849979 (Pubitemid 15024436)
102. Wu Z.-L., Schwartz E., Seeger R., Ladisch S., Expression of G D2 ganglioside by untreated primary human neuroblastomas. Cancer Research 1986 46 1 440 443 2-s2.0-0022559676 (Pubitemid 16189087)
103. Schulz G., Cheresh D. A., Varki N. M., Yu A., Staffileno L. K., Reisfeld R. A., Detection of ganglioside G D2 in tumor tissues and sera of neuroblastoma patients. Cancer Research 1984 44 12, part 1 5914 5920 2-s2.0-0021726250 (Pubitemid 15183611)
104. Zhang S., Zhang H. S., Cordon-Cardo C., Reuter V. E., Singhal A. K., Lloyd K. O., Livingston P. O., Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. International Journal of Cancer 1997 73 50 56 (Pubitemid 27445990)
105. Zhang S., Zhang H. S., Cordon-Cardo C., Ragupathi G., Livingston P. O., Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clinical Cancer Research 1998 4 11 2669 2676 2-s2.0-0031785581 (Pubitemid 28523492)
106. Chang H. R., Cordon-Cardo C., Houghton A. N., Cheung N. K., Brennan M. F., Expression of disialogangliosides G D2 and G D3 on human soft tissue sarcomas. Cancer 1992 70 633 638
107. Scanlan M. J., Gure A. O., Jungbluth A. A., Old L. J., Chen Y.-T., Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunological Reviews 2002 188 22 32 2-s2.0-0036813331 10.1034/j.1600-065X. 2002.18803.x (Pubitemid 35398862)
108. Simpson A. J. G., Caballero O. L., Jungbluth A., Chen Y.-T., Old L. J., Cancer/testis antigens, gametogenesis and cancer. Nature Reviews Cancer 2005 5 8 615 625 2-s2.0-23144464171 10.1038/nrc1669 (Pubitemid 41081387)
109. Ayyoub M., Taub R. N., Keohan M.-L., Hesdorffer M., Metthez G., Memeo L., Mansukhani M., Hibshoosh H., Hesdorffer C. S., Valmori D., The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immunity 2004 4 article 7 2-s2.0-13444310785
110. Jungbluth A. A., Antonescu C. R., Busam K. J., Iversen K., Kolb D., Coplan K., Chen Y. T., Stockert E., Ladanyi M., Old L. J., Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. International Journal of Cancer 2001 94 2 252 256 2-s2.0-0035888172 10.1002/ijc.1451 (Pubitemid 32911421)
111. Jungbluth A. A., Chen Y. T., Stockert E., Busam K. J., Kolb D., Iversen K., Coplan K., Williamson B., Altorki N., Old L. J., Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. International Journal of Cancer 2001 92 6 856 860 (Pubitemid 32467376)
112. Skubitz K. M., Pambuccian S., Carlos J. C., Skubitz A. P. N., Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. Journal of Translational Medicine 2008 6 article 23 2-s2.0-44949231208 10.1186/1479-5876-6-23 (Pubitemid 351803823)
113. Pollack S. M., Jungbluth A. A., Hoch B. L., Farrar E. A., Bleakley M., Schneider D. J., Loggers E. T., Rodler E., Eary J. F., Conrad E. U., Jones R. L., Yee C., NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 2012 118 4564 4570 2-s2.0-84857215390 10.1002/cncr.27446
114. Rosenberg S. A., Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nature Reviews Clinical Oncology 2011 8 10 577 585 2-s2.0-80053567512 10.1038/nrclinonc.2011.116
115. Robbins P. F., Morgan R. A., Feldman S. A., Yang J. C., Sherry R. M., Dudley M. E., Wunderlich J. R., Nahvi A. V., Helman L. J., Mackall C. L., Kammula U. S., Hughes M. S., Restifo N. P., Raffeld M., Lee C.-C. R., Levy C. L., Li Y. F., El-Gamil M., Schwarz S. L., Laurencot C., Rosenberg S. A., Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology 2011 29 7 917 924 2-s2.0-79952304769 10.1200/JCO.2010.32.2537
116. Natali P. G., Nicotra M. R., Bigotti A., Venturo I., Marcenaro L., Giacomini P., Russo C., Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proceedings of the National
117. Davila M. L., Brentjens R., Wang X., Rivière I., Sadelain M., How do CARs work? Early insights from recent clinical studies targeting CD19. Oncoimmunology 2012 1 1577 1583
118. Pule M. A., Savoldo B., Myers G. D., Rossig C., Russell H. V., Dotti G., Huls M. H., Liu E., Gee A. P., Mei Z., Yvon E., Weiss H. L., Liu H., Rooney C. M., Heslop H. E., Brenner M. K., Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine 2008 14 11 1264 1270 2-s2.0-55549145071 10.1038/nm.1882
119. Kochenderfer J. N., Yu Z., Frasheri D., Restifo N. P., Rosenberg S. A., Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010 116 19 3875 3886 2-s2.0-77957756405 10.1182/blood-2010-01-265041
120. Kershaw M. H., Westwood J. A., Parker L. L., Wang G., Eshhar Z., Mavroukakis S. A., White D. E., Wunderlich J. R., Canevari S., Rogers-Freezer L., Chen C. C., Yang J. C., Rosenberg S. A., Hwu P., A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research 2006 12 20 6106 6115 2-s2.0-33750699642 10.1158/1078-0432.CCR-06-1183 (Pubitemid 44703776)
121. Lamers C. H. J., Sleijfer S., Vulto A. G., Kruit W. H. J., Kliffen M., Debets R., Gratama J. W., Stoter G., Oosterwijk E., Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. Journal of Clinical Oncology 2006 24 13 e20 22 2-s2.0-33646440024 10.1200/JCO.2006.05.9964
122. Till B. G., Jensen M. C., Wang J., Chen E. Y., Wood B. L., Greisman H. A., Qian X., James S. E., Raubitschek A., Forman S. J., Gopal A. K., Pagel J. M., Lindgren C. G., Greenberg P. D., Riddell S. R., Press O. W., Adoptive immunotherapy for indolent non-hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008 112 6 2261 2271 2-s2.0-50549096284 10.1182/blood-2007-12-128843
123. Park J. R., DiGiusto D. L., Slovak M., Wright C., Naranjo A., Wagner J., Meechoovet H. B., Bautista C., Chang W.-C., Ostberg J. R., Jensen M. C., Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Molecular Therapy 2007 15 4 825 833 2-s2.0-33947265424 10.1038/sj.mt.6300104 (Pubitemid 46432004)
124. Shaffer D. R., Cruz C. R. Y., Rooney C. M., Curiel T. J., Adoptive T cell transfer. Cancer Immunotherapy 2012 New York, NY, USA Springer 47 70 10.1007/978-1-4614-4732-0-3
125. Eshhar Z., Waks T., Gross G., Schindler D. G., Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America 1993 90 2 720 724 2-s2.0-0027471898 10.1073/pnas.90.2.720 (Pubitemid 23028937)
126. Kobata T., Agematsu K., Kameoka J., Schlossman S. F., Morimoto C., CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. Journal of Immunology 1994 153 12 5422 5432 2-s2.0-0028152540 (Pubitemid 24377678)
127. Schwartz R. H., Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992 71 7 1065 1068 2-s2.0-0027087331 10.1016/S0092-8674(05)80055-8 (Pubitemid 23016541)
128. Watts T. H., TNF/TNFR family members in costimulation of T cell responses. Annual Review of Immunology 2005 23 23 68 2-s2.0-17644389199 10.1146/annurev.immunol.23.021704.115839 (Pubitemid 40563164)
129. Carpenito C., Milone M. C., Hassan R., Simonet J. C., Lakhal M., Suhoski M. M., Varela-Rohena A., Haines K. M., Heitjan D. F., Albelda S. M., Carroll R. G., Riley J. L., Pastan I., June C. H., Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America 2009 106 9 3360 3365 2-s2.0-62549097817 10.1073/pnas.0813101106
130. + T cell-mediated tumor eradication. Molecular Therapy 2010 18 2 413 420 2-s2.0-76349087378 10.1038/mt.2009.210
131. Brentjens R. J., Davila M. L., Riviere I., Park J., Wang X., Cowell L. G., Bartido S., Stefanski J., Taylor C., Olszewska M., Borquez-Ojeda O., Qu J., Wasielewska T., He Q., Bernal Y., Rijo I. V., Hedvat C., Kobos R., Curran K., Steinherz P., Jurcic J., Rosenblat T., Maslak P., Frattini M., Sadelain M., CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science Translational Medicine 2013 5 177 177ra138 10.1126/scitranslmed.3005930